Integrated DNA Technologies (IDT) announced this week that that is acquiring next-generation sequencing research assays from medical genetics company Invitae for $48 million.
The integration of IDT’s portfolio with the acquired research assays will empower labs with an all-in-one solution for uncovering biomarkers and advancing cancer discoveries, IDT said. An assay is a laboratory test to find and measure the amount of a specific substance.
The acquisition will “enable IDT to provide researchers with all-in-one NGS research solutions to uncover novel biomarkers, including critical cancer fusions,” according to a press release.
The transaction will bring more than 100 new associates under the IDT umbrella.
In March of last year, IDT acquired Coralville-based IDT acquires Swift Biosciences.